These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8053654)

  • 1. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis.
    Lindsey JW; Hodgkinson S; Mehta R; Mitchell D; Enzmann D; Steinman L
    Ann Neurol; 1994 Aug; 36(2):183-9. PubMed ID: 8053654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.
    Rep MH; van Oosten BW; Roos MT; Adèr HJ; Polman CH; van Lier RA
    J Clin Invest; 1997 May; 99(9):2225-31. PubMed ID: 9151795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis.
    van der Lubbe PA; Breedveld FC; Tak PP; Schantz A; Woody J; Miltenburg AM
    J Autoimmun; 1997 Feb; 10(1):87-97. PubMed ID: 9080303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients.
    Racadot E; Rumbach L; Bataillard M; Galmiche J; Henlin JL; Truttmann M; Herve P; Wijdenes J
    J Autoimmun; 1993 Dec; 6(6):771-86. PubMed ID: 8155256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Open therapeutic trial of anti-T CD4 monoclonal antibody in multiple sclerosis].
    Rumbach L; Racadot E; Bataillard M; Galmiche J; Henlin JL; Trutmann M; Ziegler F; Wijdenes J
    Rev Neurol (Paris); 1994; 150(6-7):418-24. PubMed ID: 7747009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis.
    Lindsey JW; Hodgkinson S; Mehta R; Siegel RC; Mitchell DJ; Lim M; Piercy C; Tram T; Dorfman L; Enzmann D
    Neurology; 1994 Mar; 44(3 Pt 1):413-9. PubMed ID: 8145907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients.
    Rumbach L; Racadot E; Armspach JP; Namer IJ; Bonneville JF; Wijdenes J; Marescaux C; Herve P; Chambron J
    Mult Scler; 1996 Feb; 1(4):207-12. PubMed ID: 9345436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers.
    Michałowska-Wender G; Losy J; Wender M; Januszkiewicz-Lewandowska D; Nowak J
    Pol J Pharmacol; 2003; 55(5):877-80. PubMed ID: 14704481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune surveillance in multiple sclerosis patients treated with natalizumab.
    Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
    Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular approaches toward a therapy for multiple sclerosis.
    Steinman L
    Riv Neurol; 1987; 57(3):173-4. PubMed ID: 2960007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis.
    Bowen JD; Petersdorf SH; Richards TL; Maravilla KR; Dale DC; Price TH; St John TP; Yu AS
    Clin Pharmacol Ther; 1998 Sep; 64(3):339-46. PubMed ID: 9757158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis.
    Maurice MM; van der Graaff WL; Leow A; Breedveld FC; van Lier RA; Verweij CL
    Arthritis Rheum; 1999 Oct; 42(10):2166-73. PubMed ID: 10524689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule.
    Troadec S; Bès C; Chentouf M; Nguyen B; Briant L; Jacquet C; Chebli K; Pugnière M; Roquet F; Cerutti M; Chardès T
    Clin Immunol; 2006 Apr; 119(1):38-50. PubMed ID: 16426893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis.
    Moreland LW; Bucy RP; Tilden A; Pratt PW; LoBuglio AF; Khazaeli M; Everson MP; Daddona P; Ghrayeb J; Kilgarriff C
    Arthritis Rheum; 1993 Mar; 36(3):307-18. PubMed ID: 8095785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab in the treatment of patients with multiple sclerosis: first experience.
    Mareckova H; Havrdova E; Krasulova E; Vankova Z; Koberová M; Sterzl I
    Ann N Y Acad Sci; 2007 Sep; 1110():465-73. PubMed ID: 17911462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of pigs with low doses of monoclonal antibodies against porcine CD4 and CD8 antigens.
    Lohse L; Nielsen J; Eriksen L
    APMIS; 2006 Jan; 114(1):23-31. PubMed ID: 16499657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with a chimeric monoclonal anti-CD4 antibody in the treatment of refractory rheumatoid arthritis.
    Moreland LW; Pratt PW; Sanders ME; Koopman WJ
    Clin Exp Rheumatol; 1993; 11 Suppl 8():S153-9. PubMed ID: 8100752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From treatment of experimental allergic encephalomyelitis to clinical trials in multiple sclerosis.
    Steinman L; Lindsey JW; Alters S; Hodgkinson S
    Immunol Ser; 1993; 59():253-60. PubMed ID: 8461390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.